Subscribe to RSS
DOI: 10.1055/s-0043-112334
Die Forschung der Dermatologischen Klinik heute – Fokus Immuntherapien in Dermatoonkologie und schweren entzündlichen Hautkrankheiten
Research at the Department of Dermatology, USZ-Today – Focus on Immuno- and Targeted Therapies in Dermatooncology and Severe Inflammatory Skin DiseasesPublication History
Publication Date:
12 July 2017 (online)
Zusammenfassung
Die nachfolgend vorgestellten Publikationen dienen exemplarisch zur Beleuchtung des Fokus der Forschung der Dermatologischen Klinik des UniversitätsSpitals Zürich auf schwere entzündliche Hautkrankheiten und auf die Dermatoonkologie. Sie reflektieren beispielhaft die umfangreiche publizistische Aktivität der Klinik und geben Einblick in die Forschungsschwerpunkte wie metastasierendes Melanom, schwere entzündliche Hautkrankheiten wie beispielsweise Pyoderma gangrenosum und der Mycosis fungoides/dem Sézary Syndrom.
Abstract
The publications presented below serve as an example to illustrate the focus of research of the Department of Dermatology of University Hospital Zurich on severe inflammatory skin diseases and on dermato-oncology. They reflect, for example, the extensive publicist activity of the department and give insights into research areas such as metastasizing melanoma, severe inflammatory skin diseases such as, for example, Pyoderma gangrenosum and Mycosis fungoides/Sézary syndrome.
-
Literatur
- 1 Frauchiger AL, Mangana J, Rechsteiner M. et al. Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation status. Br J Dermatol 2016; 174: 823-830
- 2 Kolios AG, Maul JT, Meier B. et al. Canakinumab in adults with steroid-refractory pyoderma gangrenosum. Br J Dermatol 2015; 173: 1216-1223
- 3 Mehra T, Ikenberg K, Moos RM. et al. Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome. JAMA Dermatol 2015; 151: 73-77
- 4 Duvic M, Tetzlaff MT, Gangar P. et al. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. J Clin Oncol 2015; 33: 3759-3765
- 5 Kim YH, Tavallaee M, Sundram U. et al. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sezary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. J Clin Oncol 2015; 33: 3750-3758